Eagle Asset Management Inc 89bio, Inc. Transaction History

Eagle Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$7.31 - $10.9 $4.76 Million - $7.1 Million	-651,109 Reduced 95.78%	28,658 $229,000
Q1 2024 May 09, 2024	SELL	$8.13 - $13.77 $181,526 - $307,456	-22,328 Reduced 3.18%	679,767 $7.91 Million
Q4 2023 Feb 12, 2024	SELL	$6.66 - $16.03 $71,947 - $173,172	-10,803 Reduced 1.52%	702,095 $7.84 Million
Q3 2023 Nov 13, 2023	BUY	$15.06 - $19.41 $859,805 - $1.11 Million	57,092 Added 8.71%	712,898 $11 Million
Q2 2023 Aug 09, 2023	BUY	$14.15 - $22.03 $9.28 Million - $14.4 Million	655,806 New	655,806 $12.4 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $371M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.